Current therapy for hepatitis C: pegylated interferon and ribavirin

Size: px
Start display at page:

Download "Current therapy for hepatitis C: pegylated interferon and ribavirin"

Transcription

1 Clin Liver Dis 7 (2003) Current therapy for hepatitis C: pegylated interferon and ribavirin John G. McHutchison, MD a, Michael W. Fried, MD b, * a Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27710, USA b Division of Digestive Diseases, University of North Carolina at Chapel Hill, Room 708, Chapel Hill CB #7080, 1111 Bioinfomatics Building, Chapel Hill, NC , USA Recent data have suggested that pegylation of interferon produces novel compounds with improved efficacy when compared with standard interferon preparations for treating chronic hepatitis C. The pharmacokinetic properties of these agents, peginterferon alfa-2a (PEGASYS) and peginterferon alfa-2b (PEG- INTRON), are reviewed elsewhere in this issue. This article focuses on recent results of clinical trials of these agents that have set new standards of care for treating chronic hepatitis C. Peginterferon alfa-2a Peginterferon alfa-2a monotherapy Peginterferon alfa-2a has demonstrated superiority over standard interferon alfa-2a for treating chronic hepatitis C. Zeuzem et al randomized 531 patients with chronic hepatitis C to two treatment arms with either peginterferon alfa-2a 180mg once per week for 48 weeks or standard interferon alfa-2a 6 mu three times weekly followed by 3 MU three times weekly for an additional 36 weeks [1]. Sustained virological response in the peginterferon treatment group was significantly greater than in the group treated with standard interferon (39% versus 19%, P = 0.001). Using multiple regression logistical analysis, several Dr. McHutchison has received research support from Schering Plough and Roche and is a member of the speakers bureau for both companies. Dr McHutchison has also acted as a consultant and advisor for Schering Plough. Dr. Fried is funded in part by RO-1 HL Dr. Fried receives research support from Hoffman-LaRoche and Schering. * Corresponding author. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27710, USA /03/$ see front matter D 2003, Elsevier Science (USA). All rights reserved. PII: S (02)

2 150 J.G. McHutchison, M.W. Fried / Clin Liver Dis 7 (2003) pretreatment variables were associated with increased likelihood of response to peginterferon alfa-2a monotherapy. Thus, non-1 genotype, age younger than 40 years, absence of significant fibrosis, lower body surface area, and low levels of hepatitis C virus (HCV) RNA (< 2 million copies/ml) were among the variables associated independently with sustained virological response, similar to predictive factors reported from other studies. Serum alanine transferase (ALT) activity quotient (> 3 upper limit of normal) was also associated with increased response [1]. The improved efficacy of peginterferon over standard interferon was achieved without a significant increase in toxicity. Adverse events were typical for those expected from interferon-based regimens and were similar between the two treatment arms. Self-reported depression was less in patients treated with peginterferon alfa-2a than those treated with standard interferon alfa-2a (16% versus 23%), a theme that would be repeated with peginterferon alfa-2a combination therapy. Peginterferon alfa-2a and cirrhosis Patients with hepatitis C who have developed bridging fibrosis or cirrhosis are, arguably, those with the greatest need for immediate and effective antiviral therapy to prevent further progression and to minimize their chances for future hepatic decompensation. When interferon monotherapy proved disappointing in this patient population, the presence of cirrhosis was considered a relative contraindication to therapy. Interest in treating this population was revived, however, when the combination of standard interferon alfa-2b and ribavirin demonstrated reasonable efficacy in a post hoc analysis of patients with significant fibrosis who had been included in the trial [2]. Heathcote et al [3] reported the results of a randomized phase II clinical trial specifically designed to evaluate the response to peginterferon alfa-2a prospectively in a large cohort of patients with advanced fibrosis. Two hundred seventyone patients with bridging fibrosis or cirrhosis were randomized to receive peginterferon alfa-2a 90 mg or 180 mg once per week or standard interferon alfa-2a 3 mu three times weekly for 48 weeks. Sustained virological response was achieved in 30% of those treated with the higher dose of peginterferon alfa-2a, compared with only 8% of those treated with standard interferon alfa-2a ( P = 0.001). Pretreatment characteristics associated with virological response were similar to the earlier trials; increased response was seen in those with non-1 genotype and lower viral levels. Patients underwent liver biopsy before and 6 months after completing treatment. Histologic response (a decrease of Histologic Activity Index of 2 points) was significantly greater in the peginterferon alfa-2a treatment group compared with the standard interferon group (54% versus 31%, P = 0.02). The greatest degree of histological response was found in those with sustained virological response, regardless of treatment group, although 35% of those without a sustained virological response still had a histological response after treatment with the higher dose of peginterferon [3].

3 J.G. McHutchison, M.W. Fried / Clin Liver Dis 7 (2003) Peginterferon alfa-2a and ribavirin The previous discussion described several clinical trials that demonstrated the improved efficacy of peginterferon alfa-2a over unmodified interferon. It was logical to assume that the beneficial effects on sustained virological response that occur when standard interferon is combined with ribavirin would be enhanced further when peginterferon is administered in combination with ribavirin. Fried et al recently reported the results of a large registration trial of over 1100 subjects with chronic hepatitis C who were randomized to receive peginterferon alfa-2a 180 mg weekly alone, or in combination with ribavirin 1000 mg to 1200 mg daily for 48 weeks [4] (Tables 1 3). These regimens were compared with treatment with standard interferon alfa-2b and ribavirin. The study groups were matched well; approximately 66% of the patients were genotype 1, and most had high levels of viremia (>2 million copies/ml). Patients treated with peginterferon alfa-2a plus ribavirin achieved a significantly higher sustained virological response (56%) than those treated with interferon alfa-2b plus ribavirin Table 1 Sustained virological response as a function of pretreatment characteristics Variable Peginterferon alpha-2a + ribavirin (n = 453) Interferon alpha-2b + ribavirin (n = 444) Peginterferon alpha-2a + placebo (n = 224) HCV genotype All patients 56% a 44% 29% Genotype 1 46% b 36% 21% Genotypes 2, 3 76% c 61% 45% Genotype 4 77% d 36% 44% Baseline HCV RNA copies/ml 62% e 52% 46% > copies/ml 53% f 41% 22% HCV genotype and baseline HCV RNA Genotype copies/ml 56% 43% 39% > copies/ml 41% 33% 13% Genotypes 2 and copies/ml 81% 65% 58% > copies/ml 74% 58% 40% Histological diagnosis Cirrhosis 43% 33% 21% a P < 0.001, peginterferon alpha-2a + ribavirin versus interferon alpha-2b + ribavirin. b P = 0.01, peginterferon alpha-2a + ribavirin versus interferon alpha-2b + ribavirin. c P = 0.005, peginterferon alpha-2a + ribavirin versus interferon alpha-2b + ribavirin. d No P value calculated because of to small sample size. e P = 0.04, peginterferon alpha-2a + ribavirin versus interferon alpha-2b + ribavirin. f P = 0.003, peginterferon alpha-2a + ribavirin versus interferon alpha-2b + ribavirin. Adapted from Fried MW, Shiffman ML, Reddy KR, et al. Combination of peginterferon alpha-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002;347:

4 152 J.G. McHutchison, M.W. Fried / Clin Liver Dis 7 (2003) Table 2 Frequency of discontinuations and dose modifications for peginterferon alpha-2a and ribavirin compared to standard interferon alpha-2b and ribavirin Peginterferon alpha-2a and ribavirin Interferon alpha-2b and ribavirin Discontinuation (total) 10% 11% Adverse event 7% 10% Laboratory abnormality 3% 1% Dose modifications Peginterferon Ribavirin Interferon Ribavirin Adverse event 11% 22% 11% 21% Anemia 1% 22% 3% 19% Neutropenia 20% 1% 5% < 1% Thrombocytopenia 4% < 1% < 1% < 1% (44%) or peginterferon alfa-2a plus placebo (29%; all P < 0.001) (Table 1). Patients with HCV genotype 1 also had increased sustained response with peginterferon combination therapy than with standard interferon and ribavirin (46% versus 36%, P = 0.01). Sustained virological response was achieved in 76% of patients with genotype 2 or 3 with peginterferon alfa-2a plus ribavirin, compared with 61% of those treated with standard interferon alfa-2b and ribavirin. Of note, a greater proportion of participants with combined viral characteristics associated with resistance to therapy, HCV genotype 1, and high levels of viremia (>2 million copies/ml) had sustained virological response with peginterferon alfa-2a and ribavirin than with standard interferon and ribavirin (41% versus 33%). Responses also were improved in cirrhotic patients when treated with the Table 3 Frequency of adverse events of peginterferon alpha-2a and ribavirin compared with standard interferon alpha-2b and ribavirin Peginterferon alpha-2a and ribavirin Interferon alpha-2b and ribavirin Fatigue 54% 55% Headache 47% 52% Pyrexia 43% 56% Myalgia 42% 50% Rigors 24% 35% Insomnia 37% 39% Nausea 29% 33% Alopecia 28% 34% Irritability 24% 28% Arthralgia 27% 25% Anorexia 21% 22% Dermatitis 21% 18% Depression 22% 30% Adverse events in bold print indicate lower frequencies for peginterferon alpha-2a and ribavirin compared with standard interferon and ribavirin (> 5% difference).

5 J.G. McHutchison, M.W. Fried / Clin Liver Dis 7 (2003) peginterferon and ribavirin (43% versus 33%) (Table 1). Three factors were found to be associated independently with sustained virological response: HCV non-1 genotype (odds ratio, 3.25; confidence interval, ; P < 0.001), age younger than 40 years (odds ratio, 2.6; confidence interval, ; P < 0.001), and body weight less than 75 kg (odds ratio, 1.9; confidence interval, ; P = 0.002) [4]. Early virological response and adherence Data from trials of standard interferon and ribavirin have indicated that the absence of response to treatment by 24 weeks of therapy is highly predictive of treatment failure, as judged by sustained virological response. In the most recent trial of peginterferon alfa-2a and ribavirin, retrospective analyses yielded some important information that has significant implications for the management of patients with this new agent. Early virological response was defined as loss of HCV RNA or a decrease of HCV RNA by at least two log-folds of HCV RNA compared with baseline values (ie, a decrease from 10 6 to 10 4 copies). By week 12 of therapy, 86% of patients treated with peginterferon alfa-2a plus ribavirin had achieved early virological response. Of these, 65% subsequently achieved sustained virological response (Fig. 1). In contrast, among the 14% of patients without early virological response by week 12, only 3% went on to sustained virological response, resulting in a negative predictive value of 97% [4,5]. Thus, in the absence of an early virological response, discontinuation of therapy should be considered, because the likelihood of sustained response is negligible. These decisions must be individualized, however, and evaluated within the context of the recognized variability of HCV RNA assays. To refine the predictability of treatment response further, Ferenci et al [5] analyzed sustained response according to degree of adherence, or compliance, Fig. 1. Predictive value of early virological response to peginterferon alfa-2a and ribavirin combination therapy. (From Fried MW, Shiffman ML, Reddy KR, et al. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002;347: ; with permission.)

6 154 J.G. McHutchison, M.W. Fried / Clin Liver Dis 7 (2003) with the treatment regimen. Among patients treated with peginterferon alfa-2a combination therapy who achieved an early virological response, subsequent sustained virological response occurred in 75% of those who had maintained close adherence to the prescribed treatment regimen. In those with lesser degrees of adherence, only 48% achieved sustained virological response. Dose reduction after early virological response did not reduce substantially sustained virological response, whereas a marked reduction in sustained response was seen with premature discontinuation of treatment [5]. Thus, clinicians should make every effort to maintain patients on treatment when early virological response has been achieved and when there are no safety concerns that would preclude continued therapy. Duration of therapy Preliminary results of a prospective trial that evaluated the impact of duration of therapy and ribavirin dosage have been reported recently. In the trial by Hadziyannis et al [6], patients were stratified by genotype and randomized to receive therapy for 24 or 48 weeks duration with peginterferon alfa-2a 180 mg per week and ribavirin at doses of 800 mg/day or 1000 mg to 1200 mg/day (the latter according to body weight). The overall sustained response rate for patients treated with a regimen similar to that reported in the previous trial (peginterferon alfa-2a and ribavirin for 48 weeks) was 61%. Patients with genotype 1 benefited from the longer course of therapy using the higher doses of ribavirin (sustained response, 51%). Patients with combined unfavorable treatment characteristics, genotype 1 and high viral load, had a sustained response rate of 46% with this regimen. As anticipated, patients with genotypes 2 or 3 had similar sustained response rates with 24 or 48 weeks of therapy. Patients treated for 24 weeks with the lowest dose of ribavirin (800 mg/day) had similar, excellent response rates when compared with the higher doses of ribavirin [6]. Thus, peginterferon alfa-2a and ribavirin 800 mg/day for 24 weeks is an optimal therapy for patients with genotypes 2 or 3. Safety of peginterferon alfa-2a and ribavirin Combination therapy with peginterferon alfa-2a and ribavirin achieved a favorable side effect profile compared with the control arm of interferon alfa-2b and ribavirin [4,7]. The rate of premature withdrawal from therapy for laboratory abnormalities or adverse events was similar in the two treatment arms (10% versus 11%, respectively). Laboratory abnormalities such as neutropenia, anemia, and thrombocytopenia were the most frequent reasons for dose reduction. The frequency of dose reduction for neutropenia was greater in the peginterferon combination arm (20% versus 5%). Despite the increased rate of dose reductions, laboratory abnormalities were a rare cause of early

7 J.G. McHutchison, M.W. Fried / Clin Liver Dis 7 (2003) withdrawal (peginterferon and ribavirin, 3% versus standard interferon and ribavirin, 1%). The adverse events associated with peginterferon combination therapy were compared with those reported with standard interferon and ribavirin treatment. The types of adverse events were those generally associated with combination therapy for hepatitis C, and no new classes of adverse events were observed [7]. Most adverse events associated with peginterferon alfa-2a and ribavirin were of similar frequency or substantially less frequent than those reported for standard interferon alfa-2b and ribavirin. In particular, influenza-like symptoms (fever, myalgia, and rigors) and depression occurred less frequently in the peginterferon alfa-2a and ribavirin treatment group [4,7]. Peginterferon alfa-2b Peginterferon alfa-2b monotherapy A phase III trial reported by Lindsay et al [8] indicated that peginterferon alfa-2b administered as a single agent for 48 weeks doubles the sustained virologic response rate to approximately 23% to 25% compared with standard interferon alfa-2b monotherapy. It was not effective for most patients with HCV genotype 1, however, and relapse rates after 1 year of peginterferon alfa-2b monotherapy remained high (40% to 50%) [8]. Peginterferon alfa-2b also was shown to be tolerated well, with a similar adverse effect profile compared with its standard counterpart. Peginterferon alfa-2b and ribavirin As noted previously, the addition of ribavirin in combination with peginterferon alfa-2b was likely to enhance the sustained response rates for the treatment of chronic hepatitis C. Manns et al [9] recently reported the results of a phase III randomized trial assessing the safety and efficacy of peginterferon alfa-2b combined with ribavirin for initial treatment of patients with chronic hepatitis C [4]. In this study, 1530 patients with compensated chronic HCV infection and elevated liver tests were randomized to receive one of three treatment regimens: (1) peginterferon alfa-2b 1.5 ug/kg/week plus ribavirin 800 mg/day for 48 weeks, (2) peginterferon alfa-2b 1.5 mg/kg/week plus ribavirin 1000 mg to 1200 mg/day for 4 weeks followed by peginterferon alfa-2b 0.5 ug/kg/week plus ribavirin 1000 mg to 1200 mg/day for an additional 44 weeks, or (3) standard interferon alfa-2b 3 mu subcutaneously three times weekly plus ribavirin 1000 mg to 1200 mg/day for 48 weeks. The doses of peginterferon alfa-2b were adjusted for the patient s weight and were chosen according to the most efficacious doses that led to early viral clearance in prior studies. Eight hundred milligrams of ribavirin was combined with the higher dose of pegylated interferon because of concern that when combined this

8 156 J.G. McHutchison, M.W. Fried / Clin Liver Dis 7 (2003) regimen may result in a greater degree of anemia. The groups were matched according to their baseline demographics: male (65%), mean age 43 years, pretreatment HCV RNA less than (68%), cirrhosis (10%), HCV genotype 1 (68%), and the proportion with high viral load (68%). The sustained virologic response rates for the three treatment groups are shown in Table 4 by intention to treat analysis and indicate a significantly higher sustained virologic response rates for patients receiving the higher dose peginterferon alfa-2b and ribavirin combination. Sustained response rates also were increased for patients with genotype 1 (42% versus 33%) compared with standard interferon and ribavirin [9]. Additionally, more than 90% of patients who achieved a sustained virologic response also had normal ALT values at the end of the follow-up period. As in prior HCV treatment trials, histologic inflammation improved in all treatment groups and was most evident in those who achieved a sustained response. Forty-four percent of nonresponder patients also had some improvement in histologic inflammation (Fig. 2). In this peginterferon alfa-2b/ribavirin trial as in prior interferon/ribavirin trials, a secondary analysis identified body weight as an independent predictor of sustained response [9]. Thus, a retrospective categorical analysis also indicated that the sustained response rate was related significantly to the dose of ribavirin on a milligram per kilogram basis (the optimal dose of ribavirin for this combination was identified as 13 mg ± 2 mg/kg). This effect was independent of HCV genotype. Patients who received the higher dose peginterferon in combination with more than 10.6 mg/kg of ribavirin (equivalent to 800 mg/day Table 4 Virologic sustained response rates for peginterferon alpha-2b and ribavirin Sustained virologic response rate (number responding/total treated) PegIFN 1 5 mg/kg + R (n = 511) PegIFN 1.5/0.5 5 mg/kg + R (n = 514) IFN 3 MIU + R (n = 505) End of follow-up (SVR): 54% 47% 47% all patients a SVR by genotype 1 b 42% 34% 33% 2/3 82% 80% 79% 4/5/6 50% 33% 38% SVR by baseline HCV > 2 M 42% 42% 42% 2 M 78% 59% 56% SVR by degree of fibrosis No/minimal fibrosis 57% 51% 49% Bridging fibrosis/cirrhosis 44% 43% 41% Abbreviations: IFN, interferon alpha-2b; MIU, million international unit; PegIFN, peginterferon alpha-2b; R, ribavirin; SVR, sustained virologic response calculated as the number of patients responding who had undetectable HCV RNA 24 weeks after completion of therapy per the total number treated in each group. a P = 0.01 (1.5/R versus I/R); P = 0.73 (0.5/R versus I/R) using logistic regression. b P = 0.01 (1.5/R versus I/R) by Fisher s exact test.

9 J.G. McHutchison, M.W. Fried / Clin Liver Dis 7 (2003) Fig. 2. Sustained response as a function of ribavirin dose in milligrams per kilogram and dose of peginterferon alfa-2b. This logistic regression analysis indicates that the doses of peginterferon ( P = 0.002) and ribavirin ( P = 0.015) predict sustained response. (Adapted from Manns MP, Mc- Hutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis: a randomized trial. Lancet 2001;358:958 65; with permission.) for a 75 kg patient) had an enhanced sustained response rate (61%). These response rates are illustrated in Table 5. Predicting response and early stopping rules Pretreatment factors associated with a greater likelihood of achieving a sustained response include genotype 2 or 3 infection, lower viral burden, the absence of significant fibrosis, young age, and female gender [9]. Although these factors provide an estimate of the chances of achieving a response, they are generally unhelpful in accurately identifying patients who will respond to Table 5 Sustained virologic response rates by pretreatment variables and according to ribavirin dosage PegIFN 1 5 mg/kg + R (n = 511) PegIFN 1.5/0.5 5 mg/kg + R (n = 514) IFN 3 MIU + R (n = 505) All patients 54% 47% 47% Ribavirin dose 10.6 mg/kg 50% 41% 27% Ribavirin dose >10.6 mg/kg 61% 48% 47% Genotype 1 42% 34% 33% Ribavirin dose 10.6 mg/kg 38% 25% 20% Ribavirin dose >10.6 mg/kg 48% 34% 34% Response rates for each treatment group are shown as a percentage according to each pre-treatment variable. For each variable, response rates are also shown according to whether the patients in each subgroup received >10 6 mg/kg or 10 6 mg/kg ribavirin. Abbreviations: IFN, interferon alpha-2b; MIU, million international unit; PegIFN, peginterferon alpha-2b; R, ribavirin; SVR, sustained virologic response. Adapted from Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:

10 158 J.G. McHutchison, M.W. Fried / Clin Liver Dis 7 (2003) therapy. The ideal test to predict response should be able to identify all nonresponder patients early during therapy, so they may cease therapy and thus avoid the morbidity and expense of prolonged therapy, while continuing treatment in those who eventually will achieve sustained response. Preliminary analyses from the phase III peginterferon alfa-2b/ribavirin trial indicate that 100% of patients receiving peginterferon and ribavirin who fail to achieve a 2 log (100-fold) reduction in serum HCV RNA by week 12 of therapy will be eventual nonresponders [10]. In addition, those individuals who achieve a 2-log reduction by this time point have an 80% chance of achieving a sustained response. Although these rules most accurately predict nonresponse, a number of caveats should be considered when using these data clinically. First, they do not take into account the potential histologic benefits observed in nonresponder patients [11], and second, the limitations of these quantitative HCV RNA assays in terms of their variability and precision may confound interpretation of viral load changes during therapy [12]. Thus, these early stopping rules must be used cautiously, and if doubt exists, the clinician should consider retesting and giving the patient the benefit of the doubt before considering ceasing therapy in the situation where an eventual nonresponse is highly likely. Adherence and its effect on response rates with peginterferon alfa-2b and ribavirin Dosing of peginterferon alfa-2b and ribavirin requires a modestly complex regimen of injections, daily oral medication, and frequent office visits and blood tests to monitor safety. As a result, not all patients complete treatment. A retrospective analysis of the effect of adherence or compliance on sustained response rates in the setting of peginterferon alfa-2b and ribavirin recently was completed [13]. In this trial, overall, 63% of patients who received at least 80% of expected doses of peginterferon alfa-2b 1.5 mg/kg and ribavirin 800 mg/day for at least 80% of the recommended duration of therapy achieved an SVR (compared with 54% overall). With 80 plus 80 plus 80 adherence to the regimen of peginterferon (1.5 mg/kg) and ribavirin (>10.6 mg/kg), the response rate increased from 61% overall to 72%. The impact of adherence to therapy was most significant in patients with genotype I infection; the SVR rate was 63% among adherent patients compared with 34% among nonadherent patients according to these 80% criteria. Thus, patients who can be maintained on at least 80% of their peginterferon dose and at least 80% of their ribavirin dose may have an enhanced SVR rate. Nearly 75% of patients with 80 plus 80 plus 80 adherence to a prescribed regimen of at least 1.5 ug/kg peginterferon alfa-2b and more than 10.6 mg/kg ribavirin for 48 weeks can achieve an SVR. Patients infected with HCV genotype 1 the most difficult to treat stand to benefit the most from adherence, especially in the first 12 to 24 weeks of therapy, when a determination as to who is most likely to achieve an eventual sustained response can be evaluated.

11 J.G. McHutchison, M.W. Fried / Clin Liver Dis 7 (2003) Effect of therapy on fibrosis progression rates The effect of pegylated interferon alfa-2b and ribavirin (and other treatment regimens) on fibrosis progression was evaluated recently in a pooled study of 3010 patients from four trials [11]. In this cohort, treatment reduced the rate of fibrosis progression compared with that observed prior to therapy, and this was most evident for patients treated with peginterferon alfa-2b and ribavirin. Fiftytwo percent of patients who were treated with the high-dose peginterferon and ribavirin (>10.6 mg/kg) regimen had reversal of cirrhosis on their subsequent post-treatment biopsy. Although controversial, the results of this study provide substantial evidence that effective treatment associated with sustained virologic eradication can be linked to improvement in the severity of liver fibrosis (see the article in this issue by Bedossa for more detailed information). Cost effectiveness of peginterferon alfa-2b and ribavirin antiviral therapy The short- and long-term benefits of antiviral therapy have allowed economic and cost-effective analysis of antiviral treatment [14]. Results of these studies indicate that antiviral therapy with interferon (standard or pegylated) plus ribavirin is cost-effective and economically feasible when compared with other accepted medical practices (such as screening for hypertension, colorectal cancer, or mammography). In addition, patients who have sustained viral eradication have improvement in their health-related quality of life. Safety of peginterferon alfa-2b and ribavirin The adverse event profile of peginterferon alfa-2b and ribavirin was similar to adverse events observed with interferon alfa-2b and ribavirin. Discontinuations caused by adverse events were observed in 13% (interferon and ribavirin group), 13% (low dose peginterferon and ribaviron group), and 14% (higher dose peginterferon and ribavirin) of patients respectively. Additionally, dose modifications were reported in 34%, (interferon and ribavirin group) 36%, (low dose peginterferon and ribavirin) and 42% (higher dose peginterferon and ribavirin) of the patients in these three treatment groups. Adverse events during therapy were similar in the three groups, and no new adverse events were noted in the groups receiving either dose of peginterferon alfa-2b. The rate of flu-like symptoms was higher in the high-dose peginterferon group (not surprising, because more interferon was being administered), and injection-site reactions were more common but were generally mild and did not limit the course of treatment. Anemia was not observed more frequently or to a greater degree in patients who received the higher dose peginterferon, but neutropenia was observed more frequently in those receiving the higher does of peginterferon. Fewer than 1% of patients required discontinuation of therapy for neutropenia, however. A separate safety analysis of those patients who received more than 10.6 mg/kg of ribavirin

12 160 J.G. McHutchison, M.W. Fried / Clin Liver Dis 7 (2003) indicated that asthenia, weight loss, nausea, and alopecia were observed more commonly but were not dose-limiting, and the degree of anemia, or need to cease therapy, was not increased in this subgroup of patients. Summary The combinations of peginterferon alfa-2a or peginterferon alfa-2b with ribavirin lead to significant improvement in sustained virological response when compared with standard interferon and ribavirin therapy. These newer agents represent the most effective treatments available for the initial therapy of patients with chronic hepatitis C. A review of the clinical trials to date suggests certain similarities and differences between the two preparations. For both regimens, however, it is apparent that information concerning the predictability of response and the importance of adherence to the treatment regimens will be of great value in the therapeutic management of chronic hepatitis C. Although viral load and genotype, gender, age, and absence of fibrosis have been shown consistently to be important predictors of response, identification of additional host immune and genetic factors involved in determining outcome of antiviral therapy are necessary. References [1] Zeuzem S, Heathcote JE, Martin N, Nieforth K, Modi M. Peginterferon alfa-2a (40 kda) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opin Investig Drugs 2001; 10: [2] McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339: [3] Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343: [4] Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL. et al. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 2002;347: [5] Ferenci P, Shiffman ML, Fried MW, Sulkowski MS, Haeussinger D, Zarski J-P, et al. Early prediction of response to 40 kda peginterferon alfa-2a (PEGASYS) plus ribavirin in patients with chronic hepatitis C. Hepatology 2001;34:351A. [6] Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen DM, Sette H, et al. Peginterferon alpha-2a (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examing effect of duration of treatment and RBV dose [abstract]. Hepatology 2002;36:536. [7] Fried MW. Side effects of therapy for hepatitis C and their management. Hepatology, in press. [8] Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34: [9] Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358: [10] Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK. Clinical implications of testing

13 J.G. McHutchison, M.W. Fried / Clin Liver Dis 7 (2003) viral response during peginterferon alfa-2b and ribavirin treatment for chronic hepatitis C [abstract]. Hepatology, in press. [11] Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122: [12] Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000;32: [13] McHutchison JG, Manns MP, Patel K, Poynard T, Lindsay KL, Trepo C. et al. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology 2002;123: [14] Wong JB, McHutchison J, Manns M, Davis GL, Albrecht J. Effect of treatment management algorithms on peginterferon alfa-2b costs for chronic hepatitis C [abstract]. Hepatology, in press.

Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience

Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis

More information

The treatment of choice for chronic hepatitis C is

The treatment of choice for chronic hepatitis C is Early Identification of HCV Genotype 1 Patients Responding to 24 Weeks Peginterferon -2a (40 kd)/ribavirin Therapy Donald M. Jensen, 1 Timothy R. Morgan, 2 Patrick Marcellin, 3 Paul J. Pockros, 4 K. Rajender

More information

ةي : لآا ةرقبلا ةروس

ةي : لآا ةرقبلا ةروس سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a

More information

Treatment of Chronic Hepatitis C in Non-Responders

Treatment of Chronic Hepatitis C in Non-Responders Management of Patients with Viral Hepatitis, Paris, 2004 Treatment of Chronic Hepatitis C in Non-Responders Jay H. Hoofnagle INTRODUCTION The treatment of chronic hepatitis C has evolved markedly over

More information

Reviews/Evaluations. Chronic Hepatitis C. Introduction and Epidemiology. Natural Course of HCV. Recommendations for Treatment

Reviews/Evaluations. Chronic Hepatitis C. Introduction and Epidemiology. Natural Course of HCV. Recommendations for Treatment Reviews/Evaluations Chronic Hepatitis C Introduction and Epidemiology Hepatitis C virus (HCV) is one of the most common blood-borne infections and cause of chronic liver disease in the United States (1).

More information

Over the past decade, the introduction of

Over the past decade, the introduction of MANAGEMENT OF CHRONIC HEPATITIS C IN HIV-INFECTED PATIENTS: CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α PLUS RIBAVIRIN Raymond T. Chung, MD* ABSTRACT Coinfection with hepatitis C virus (HCV) is common

More information

Prospective Analysis of Patient Education Time and Administration Errors Associated with Administration of Pegasys versus Peg-Intron

Prospective Analysis of Patient Education Time and Administration Errors Associated with Administration of Pegasys versus Peg-Intron Prospective Analysis of Patient Education Time and Administration Errors Associated with Administration of Pegasys versus Peg-Intron David Finkelman, MD, MBA Janet McRea, LPN Reprint requests to: David

More information

The medical management of hepatitis C

The medical management of hepatitis C CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α-2a PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS INFECTED WITH HIV: THE APRICOT STUDY Douglas T. Dieterich, MD* ABSTRACT Currently,

More information

Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection

Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:610 615 Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection YOAV LURIE,* REGINE ROUZIER PANIS, GEORGE

More information

Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3

Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1:17 22 1 Charite Universitatsmedizin Berlin, Berlin, Germany

More information

Anemia in the Treatment of Hepatitis C Virus Infection

Anemia in the Treatment of Hepatitis C Virus Infection SUPPLEMENT ARTICLE Anemia in the Treatment of Hepatitis C Virus Infection Mark S. Sulkowski Center for Viral Hepatitis, Johns Hopkins University, Baltimore, Maryland Hepatitis C virus (HCV) infection is

More information

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center

More information

CHRONIC HCV TREATMENT: In Special Populations.

CHRONIC HCV TREATMENT: In Special Populations. CHRONIC HCV TREATMENT: In Special Populations. By Taher EL-ZANATY Prof. of Internal Medicine CAIRO UNIVERSITY Introduction: HCV is the major cause of chronic hepatitis in Egypt. Its end stage is liver

More information

TRANSPARENCY COMMITTEE

TRANSPARENCY COMMITTEE The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 REBETOL 200 mg capsules Pack of 84 (CIP code: 351 971.9) Pack of 112 (CIP code: 373 277.8) Pack of

More information

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International

More information

Technology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200

Technology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C Technology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200 NICE 2018. All rights reserved. Subject to

More information

Weight-Based Combination Therapy with Peginterferon α-2b and Ribavirin for Naïve, Relapser and Non-Responder Patients with Chronic Hepatitis C

Weight-Based Combination Therapy with Peginterferon α-2b and Ribavirin for Naïve, Relapser and Non-Responder Patients with Chronic Hepatitis C BJID 2006; 10 (October) 311 Weight-Based Combination Therapy with Peginterferon α-2b and Ribavirin for Naïve, Relapser and Non-Responder Patients with Chronic Hepatitis C Fernando Lopes Gonçales Jr. 1,

More information

29th Viral Hepatitis Prevention Board Meeting

29th Viral Hepatitis Prevention Board Meeting 29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C

More information

Pegylated interferons (peginterferons) represent the

Pegylated interferons (peginterferons) represent the Viral Kinetics in Genotype 1 Chronic Hepatitis C Patients During Therapy With 2 Different Doses of Peginterferon Alfa-2b Plus Ribavirin Maria Buti, 1 Francisco Sanchez-Avila, 1 Yoav Lurie, 2 Carlos Stalgis,

More information

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE. Final Appraisal Determination

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE. Final Appraisal Determination NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE Final Appraisal Determination Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C 1 Guidance 1.1 Combination

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pegylated interferon α 2b (ViraferonPeg ), 50, 80, 100, 120 or 150 micrograms powder for solution for injection in pre-filled pen, in combination with ribavirin (Rebetol ),

More information

Oral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside

Oral combination therapy: future hepatitis C virus treatment? Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following

More information

Treatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.

Treatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D. Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,

More information

Annals of Hepatology 2003; 2(3): July-September: Original Article

Annals of Hepatology 2003; 2(3): July-September: Original Article Annals of Hepatology 2003; 2(3): July-September: 135-139 Annals of Hepatology Original Article Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican

More information

Update on Real-World Experience With HARVONI

Update on Real-World Experience With HARVONI Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data

More information

Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C

Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.3.203 Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C Jung Hyun Kwon

More information

Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?

Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of

More information

TRANSPARENCY COMMITTEE OPINION. 10 December 2008

TRANSPARENCY COMMITTEE OPINION. 10 December 2008 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 VIRAFERONPEG 50 µg/ 0.5 ml powder and solvent for injectable solution Pack of 1 (CIP: 355 189.3)

More information

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. Part review of NICE technology appraisal guidance 75 and 106

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. Part review of NICE technology appraisal guidance 75 and 106 Issue date: September 2010 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C Part review of NICE technology appraisal guidance 75 and 106 National Institute for Health and Clinical

More information

Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy

Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy Teerha Piratvisuth MD. Prince of Songkla University Treatment of chronic hepatitis C and response rates

More information

Update on Real-World Experience With HARVONI

Update on Real-World Experience With HARVONI Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were

More information

The decision to treat hepatitis C virus. Managing Hepatitis C REPORTS. Bruce R. Bacon, MD

The decision to treat hepatitis C virus. Managing Hepatitis C REPORTS. Bruce R. Bacon, MD Bruce R. Bacon, MD Abstract Availability of a drug regimen that eradicates the hepatitis C virus (HCV) in more than half of treated patients provides the medical community with a powerful new weapon to

More information

Should Elderly CHC Patients (>70 years old) be Treated?

Should Elderly CHC Patients (>70 years old) be Treated? Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,

More information

Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial

Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1

More information

Hepatitis C virus (HCV) replicates at a rapid rate,

Hepatitis C virus (HCV) replicates at a rapid rate, Early Virologic Response to Treatment With Peginterferon Alfa-2b plus Ribavirin in Patients With Chronic Hepatitis C Gary L. Davis, 1 John B. Wong, 2 John G. McHutchison, 3 Michael P. Manns, 4 Joann Harvey,

More information

Current Standard of Care for Naïve HCV Patients (SVR)

Current Standard of Care for Naïve HCV Patients (SVR) Hepatitis C: Non-responders Nikunj Shah, MD Associate Professor of medicine University of Illinois Medical center 1 Current Standard of Care for Naïve HCV Patients (SVR) 1 8 8 6 53 45 4 6 52 46 4 2 2 Peg

More information

Intravenous drug use is currently the main transmission

Intravenous drug use is currently the main transmission A Prospective Controlled Study of Interferon-Based Therapy of Chronic Hepatitis C in Patients on Methadone Maintenance Stefan Mauss, 1 Florian Berger, 1 Joerg Goelz, 2 Bernhard Jacob, 3 and Günther Schmutz

More information

Anemia as a predictor of response to antiviral therapy in chronic hepatitis C

Anemia as a predictor of response to antiviral therapy in chronic hepatitis C DOI: 10.4149/BLL_2013_044 Bratisl Lek Listy 2013; 114 (4) CLINICAL STUDY Anemia as a predictor of response to antiviral therapy in chronic hepatitis C Urbanek P 1, Kreidlova M 2, Dusek L, 3 Bruha R 4,

More information

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients 5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,

More information

Antiviral therapy guidelines for the general population

Antiviral therapy guidelines for the general population Discussion 10 Chapter 10 Hepatitis C a worldwide problem More than 170 million people worldwide suffer from chronic hepatitis C. Its prevalence is 2% in industrialized countries. 1 Approximately 20% of

More information

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)

Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy

More information

Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon Ribavirin in daily practice

Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon Ribavirin in daily practice 46 Ridruejo E, et al., 2010; 9 (1): 46-51 ORIGINAL ARTICLE January-March, Vol. 9 No.1, 2010: 46-51 Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon

More information

Pharmacological management of viruses in obese patients

Pharmacological management of viruses in obese patients Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician

More information

Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus

Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL

More information

Therapy of Hepatitis C. Adrian M. Di Bisceglie

Therapy of Hepatitis C. Adrian M. Di Bisceglie Session V Therapy of Hepatitis C Adrian M. Di Bisceglie Saint Louis University Liver Center, St. Louis, Mo. Tremendous progress has been made in developing effective therapies for hepatitis C. The process

More information

Technology appraisal guidance Published: 28 January 2004 nice.org.uk/guidance/ta75

Technology appraisal guidance Published: 28 January 2004 nice.org.uk/guidance/ta75 Interferon alfa (pegylated and non- pegylated) and ribavirin for the treatment of chronic hepatitis C Technology appraisal guidance Published: 28 January 2004 nice.org.uk/guidance/ta75 NICE 2017. All rights

More information

HEPATITIS C TREATMENT GUIDANCE

HEPATITIS C TREATMENT GUIDANCE HEPATITIS C TREATMENT GUIDANCE These guidelines have been produced based on the NICE Guidance TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis c and the summaries of product

More information

Yun Jung Kim, Byoung Kuk Jang, Eun Soo Kim, Kyung Sik Park, Kwang Bum Cho, Woo Jin Chung, and Jae Seok Hwang

Yun Jung Kim, Byoung Kuk Jang, Eun Soo Kim, Kyung Sik Park, Kwang Bum Cho, Woo Jin Chung, and Jae Seok Hwang The Korean Journal of Hepatology 2012;18:41-47 http://dx.doi.org/10.3350/kjhep.2012.18.1.41 pissn: 1738-222X eissn: 2093-8047 Original Article Rapid normalization of alanine aminotransferase predicts viral

More information

PEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced

PEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design

More information

Treatment Outcome in Chronic Hepatitis C Infection: A Four Years Survey Among Iranian Patients

Treatment Outcome in Chronic Hepatitis C Infection: A Four Years Survey Among Iranian Patients Global Journal of Health Science; Vol. 7, No. 3; 2015 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Treatment Outcome in Chronic Hepatitis C Infection: A Four Years

More information

Hepatitis C Treatment

Hepatitis C Treatment Hepatitis C Treatment Standard of care & Managing advrse events Mohssen Nassiri Toosi, MD A s s o c i a t e P ro f e s s o r Of Internal M e d i c i n e Te h r a n U n i v e r s i t y O f M e d i c a l

More information

Improving Treatment Success Rates for HCV in a Managed Care Setting

Improving Treatment Success Rates for HCV in a Managed Care Setting Improving Treatment Success Rates for HCV in a Managed Care Setting Bruce R. Bacon, MD James F. King MD Endowed Chair in Gastroenterology Professor of Internal Medicine Division of Gastroenterology and

More information

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial Journal of Viral Hepatitis, 2007, 14, 788 796 doi:10.1111/j.1365-2893.2007.00871.x Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice:

More information

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014

More information

Monitoring of Viral Levels of Hepatitis. During Therapy. Gary L. Davis

Monitoring of Viral Levels of Hepatitis. During Therapy. Gary L. Davis Monitoring of Viral Levels of Hepatitis Gary L. Davis During Therapy Alpha interferon therapy of chronic hepatitis C is typically accompanied by a biphasic decrease in hepatitis C virus (HCV) RNA levels:

More information

Hepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011

Hepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Hepatitis C Update Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Outline n Educational Objectives Epidemiology and Natural History of Hepatitis C Current Treatment

More information

Management of chronic hepatitis C treatment failures: role of consensus interferon

Management of chronic hepatitis C treatment failures: role of consensus interferon REVIEW Management of chronic hepatitis C treatment failures: role of consensus interferon Stevan A Gonzalez 1 Emmet B Keeffe 2 1 Division of Hepatology, Baylor Regional Transplant Institute, Baylor All

More information

2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956

2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-

More information

.'URRENT THERAPEUTIC RESEARCt

.'URRENT THERAPEUTIC RESEARCt .'URRENT THERAPEUTIC RESEARCt VOLUME 66, NUMBER 5, SEPTEMBER/OCTOBER 2005 Clinical Experience with Nonstandard Doses of Interferon Alfa-2b and Ribavirin in the Treatment of Chronic Hepatitis C Infection:

More information

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:

More information

554 BJID 2007; 11 (December)

554 BJID 2007; 11 (December) 554 BJID 2007; 11 (December) Using Pegylated Interferon alfa-2b and Ribavirin to Treat Chronic Hepatitis Patients Infected with Hepatitis C Virus Genotype 1: Are Nonresponders and Relapsers Different Populations?

More information

Optimal ltherapy in non 1 genotypes:

Optimal ltherapy in non 1 genotypes: Optimal ltherapy in non 1 genotypes: genotype 2 and 3 patients Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S. University of Palermo, Italy craxanto@unipa.it Peg IFN alpha plus ribavirin : SVR rate of >80%

More information

In the United States, the recent National Health and. Predictors of Response of U.S. Veterans to Treatment for the Hepatitis C Virus

In the United States, the recent National Health and. Predictors of Response of U.S. Veterans to Treatment for the Hepatitis C Virus Predictors of Response of U.S. Veterans to Treatment for the Hepatitis C Virus Lisa I. Backus, Derek B. Boothroyd, Barbara R. Phillips, and Larry A. Mole The currently recommended treatment for hepatitis

More information

Is an À la Carte Combination Interferon Alfa-2b Plus Ribavirin Regimen Possible for the First Line Treatment in Patients With Chronic Hepatitis C?

Is an À la Carte Combination Interferon Alfa-2b Plus Ribavirin Regimen Possible for the First Line Treatment in Patients With Chronic Hepatitis C? Is an À la Carte Combination Interferon Alfa-2b Plus Ribavirin Regimen Possible for the First Line Treatment in Patients With Chronic Hepatitis C? THIERRY POYNARD, 1 JOHN MCHUTCHISON, 2 ZACHARY GOODMAN,

More information

SYNOPSIS OF RESEARCH REPORT (PROTOCOL MV22009)

SYNOPSIS OF RESEARCH REPORT (PROTOCOL MV22009) SYNOPSIS OF RESEARCH REPORT 1066781 (PROTOCOL MV22009) COMPANY: F. Hoffmann-La Roche, Ltd ME OF FINISHED PRODUCT: Pegasys ME OF ACTIVE SUBSTANCE(S): Peginterferon alfa-2a (FOR TIOL AUTHORITY USE ONLY)

More information

Developments in the Treatment of Hepatitis C: A New Era

Developments in the Treatment of Hepatitis C: A New Era Developments in the Treatment of Hepatitis C: A New Era Nancy Love, PharmD, BCPS Memorial Medical Center, Johnstown, PA October 17, 2014 Pharmacist Objectives Summarize the results of clinical trials for

More information

Pegylated Interferons and Ribavirins

Pegylated Interferons and Ribavirins Pegylated Interferons and Ribavirins Goal(s): Cover drugs only for those clients where there is evidence of effectiveness and safety Length of Authorization: 16 weeks plus 12-36 additional weeks or 12

More information

Background: Narlaprevir (SCH )

Background: Narlaprevir (SCH ) Once Daily Narlaprevir (SCH 9518) in Combination with Peginterferon alfa-2b/ Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: Interim Results from the NEXT-1 Study Vierling J,

More information

Intron A Hepatitis B. Intron A (interferon alfa-2b) Description

Intron A Hepatitis B. Intron A (interferon alfa-2b) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis

More information

New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD

New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Viral Targets for HCV New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Sites for development of inhibitors Metalloproteinase Serine protease (trans) Core E E2 NS2 NS3 NS4a/NS4b NS5a/NS5b

More information

Treatment choices for people infected with HCV

Treatment choices for people infected with HCV Journal of Antimicrobial Chemotherapy (2004) 53, 708 712 DOI: 10.1093/jac/dkh170 Treatment choices for people infected with HCV Silvia Fargion*, Anna Ludovica Fracanzani and Luca Valenti Dipartimento di

More information

Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C

Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Zobair M. Younossi, MD, MPH, FACP, FACG Medscape Gastroenterology. 2007; 2007 Medscape Posted 06/01/2007 Introduction

More information

V. Hepatitis C Treatment

V. Hepatitis C Treatment V. Hepatitis C Treatment Summary The current standard of treatment for hepatitis C virus (HCV) is a combination of two drugs: pegylated interferon and ribavirin. The virological response rate, treatment

More information

Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona

Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg

More information

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370: Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV

More information

Treatment guidance for Chronic Hepatitis C Infection

Treatment guidance for Chronic Hepatitis C Infection Treatment guidance for Chronic Hepatitis C Infection A meeting of the network was held on 11 April 2008 at which the current evidence base for hepatitis C was reviewed. These guidelines have been produced

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pegylated Interferon alfa 2a, 180 mcg for subcutaneous injection (Pegasys ) No. (186/05) Roche New indication (chronic hepatitis B) 10 June 2005 The Scottish Medicines Consortium

More information

The most effective treatment for chronic hepatis C. Treatment of Chronic Hepatitis C Virus Genotype 1 with Peginterferon, Ribavirin, and Epoetin alpha

The most effective treatment for chronic hepatis C. Treatment of Chronic Hepatitis C Virus Genotype 1 with Peginterferon, Ribavirin, and Epoetin alpha Treatment of Chronic Hepatitis C Virus Genotype 1 with Peginterferon, Ribavirin, and Epoetin alpha Mitchell L. Shiffman, Jennifer Salvatore, Sarah Hubbard, Angie Price, Richard K. Sterling, R. Todd Stravitz,

More information

Clinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.

Clinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago

More information

Research Article Impact of Hepatitis B Exposure on Sustained Virological Response Rates of Highly Viremic Chronic Hepatitis C Patients

Research Article Impact of Hepatitis B Exposure on Sustained Virological Response Rates of Highly Viremic Chronic Hepatitis C Patients Gastroenterology Research and Practice Volume 2009, Article ID 812140, 5 pages doi:10.1155/2009/812140 Research Article Impact of Hepatitis B Exposure on Sustained Virological Response Rates of Highly

More information

Efficacy of triple therapy with interferon alpha-2b, ribavirin and amantadine. in the treatment of naïve patients with chronic hepatitis C

Efficacy of triple therapy with interferon alpha-2b, ribavirin and amantadine. in the treatment of naïve patients with chronic hepatitis C Received: 15.1.2007 Accepted: 10.6.2007 Efficacy of triple therapy with interferon alpha-2b, ribavirin and amantadine in the treatment of naïve patients with chronic hepatitis C Hamid Kalantari*, Fatemeh

More information

Management of Incidental Hepatitis C Virus Infection

Management of Incidental Hepatitis C Virus Infection The new england journal of medicine Clinical Decisions Interactive at nejm.org Management of Incidental Hepatitis C Virus Infection This interactive feature addresses the diagnosis or management of a clinical

More information

Abstract 233. Post-treatment follow up. Pawlotsky JM, et al. 63rd AASLD; Boston, MA; November 9-13, 2012:. Abst ALV loading* RVR at W4

Abstract 233. Post-treatment follow up. Pawlotsky JM, et al. 63rd AASLD; Boston, MA; November 9-13, 2012:. Abst ALV loading* RVR at W4 Jean-Michel Pawlotsky, Shiv K. Sarin, Graham R. Foster, Cheng-Yuan Peng, Jens Rasenack, Robert Flisiak, Teerha Piratvisuth, Heiner Wedemeyer, Wan-Long Chuang, Wei Zhang and Nikolai V. Naoumov Abstract

More information

D. Posthouwer 1 K. Fischer 1,2 N. de Heusden 1 E.P. Mauser-Bunschoten 1

D. Posthouwer 1 K. Fischer 1,2 N. de Heusden 1 E.P. Mauser-Bunschoten 1 Pegylated interferon and ribavirin combination therapy for chronic hepatitis C in patients with inherited bleeding disorders: a single-center experience 9 D. Posthouwer 1 K. Fischer 1,2 N. de Heusden 1

More information

A "State-of-the-Art" Conference Hepatitis C: A Meeting Ground for the Generalist and the Specialist

A State-of-the-Art Conference Hepatitis C: A Meeting Ground for the Generalist and the Specialist A "State-of-the-Art" Conference Hepatitis C: A Meeting Ground for the Generalist and the Specialist Information regarding pathogenesis and appropriate management of chronic hepatitis C continues to evolve.

More information

For the RESPOND-2 Investigators

For the RESPOND-2 Investigators HCV RESPOND-2 Final Results High Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin when Re- Treated with Boceprevir Plus PEGINTRON (Peginterferon

More information

CASE STUDY. Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be?

CASE STUDY. Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be? Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be? CASE STUDY Pham Thi Thu Thuy MD, PhD Ho Chi Minh City Vietnam Serious Adverse

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 INCIVO 375 mg, film-coated tablet B/4 bottles of 42 tablets (CIP code: 217 378-5) B/1 bottle of 42

More information

1. SYNOPSIS. AWB-ML21645 Date: April 20, 2016 Title of the observational study

1. SYNOPSIS. AWB-ML21645 Date: April 20, 2016 Title of the observational study 1. SYNOPSIS AWB-ML21645 Date: April 20, 2016 Title of the observational study INVESTIGATORS SPONSOR Noninterventional study on the quality assurance of the therapy of chronic hepatitis C with Peg-(40kd)-Interferon

More information

HEPATITIS C VIRUS (HCV) GENOTYPE TESTING

HEPATITIS C VIRUS (HCV) GENOTYPE TESTING CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEPATITIS C VIRUS (HCV) GENOTYPE TESTING Policy Number: PDS - 027 Effective Date:

More information

Express Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011

Express Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011 BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)

More information

Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy

Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy ORIGINAL ARTICLE September-October, Vol. 13 No. 5, 2014: 503-509 Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy Ajit Sood, Vandana

More information

Dr. Siddharth Srivastava

Dr. Siddharth Srivastava Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.

More information

Pegasys Pegintron Ribavirin

Pegasys Pegintron Ribavirin Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron

More information

Hepatitis C Management and Treatment

Hepatitis C Management and Treatment Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause

More information

UNDESIRABLE EFFECTS DURING HEPATITIS C TREATMENT AND THEIR REMEDIES

UNDESIRABLE EFFECTS DURING HEPATITIS C TREATMENT AND THEIR REMEDIES UNDESIRABLE EFFECTS DURING HEPATITIS C TREATMENT AND THEIR REMEDIES Azmat Ali, Javaria Ilyas Shaikh, Awais Saeed Abbasi ABSTRACT Background: Hepatitis C virus (HCV) infection is one of the most important

More information

Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection

Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection GASTROENTEROLOGY 2010;138:116 122 Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection ANTONIO ASCIONE,* MASSIMO

More information

Antiviral Therapy 11: Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 2

Antiviral Therapy 11: Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 2 Antiviral Therapy 11:985 994 A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre

More information